Objective To examine the safety, effectiveness, and cost effectiveness of long acting insulin
for type 1 diabetes. Design Systematic review and network meta-analysis. Data sources …

Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal
insulin therapy in patients with type 1 or 2 diabetes mellitus. The protracted action of insulin …

Aims This study assessed the cost‐effectiveness of long‐acting insulin analogues (LAIAs) vs
intermediate/long‐acting human insulin (ILAHI) for patients with type 1 diabetes (T1D) in real …

Aim To evaluate the clinical benefits and cost‐effectiveness of the sensor‐augmented pump
compared with self–monitoring of plasma glucose plus continuous subcutaneous insulin …

Background People with type 1 diabetes mellitus (T1DM) need treatment with insulin for
survival. Whether any particular type of (ultra‐) long‐acting insulin provides benefit …

Background The economic burden of diabetes from a societal perspective is well
documented in the cost-of-illness literature. However, the effect of considering social costs in …

Background Insulin analogues have a pharmacokinetic advantage over human insulin and
are increasingly used to treat diabetes mellitus. A summary of their cost effectiveness versus …

Background Achieving good glycaemic control is essential to reducing the risk of diabetes
complications. Insulin is the most effective therapy for achieving good glycaemic control; …

Objective: To assess the cost-effectiveness of insulin detemir compared with Neutral
Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 …

Background: Two basal insulin analogues, insulin glargine once daily and insulin detemir
once or twice daily, are marketed in Canada. Objective: To estimate the long-term costs of …